Kedudukan dalam Saham
#25851
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Harga Saham
$15.31
Disegerakkan terakhir: 2024-02-29
Perubahan (1 tahun)
0.00%
Perdagangan Icosavax, Inc. (ICVX)
Harga ICVX dengan permodalan pasaran b
Modal pasaran bagi Icosavax, Inc.(ICVX)
Modal Pasaran: $45.70M
Sehingga August 2026, Icosavax, Inc. mempunyai modal pasaran sebanyak $45.70M. Ini menjadikan Icosavax, Inc. syarikat ke-25851st paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Icosavax, Inc. dari 2021 hingga 2026
ICVX berbanding dengan 5 teratas yang paling popular stocks
| Harga ICVX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.257T
|
+11,501,961.75%
|
|
|
|
|
$4.599T
|
+10,061,812.56%
|
|
|
|
|
$4.106T
|
+8,984,099.76%
|
|
|
|
|
$3.577T
|
+7,826,978.55%
|
|
|
|
|
$2.807T
|
+6,142,321.87%
|
